Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
(Q29615030)
scientific article (publication date: August 2002)
scientific article (publication date: August 2002)
Language: